Multiple Meyloma
9 important updates in blood cancer treatment, research
September is Blood Cancer Awareness Month.
Roswell Park appoints CAR T-cell pioneer as new deputy director
Renier Brentjens, MD, PhD, has been appointed deputy director and chair of the department of medicine of Roswell Park Comprehensive Cancer Center.
Patients with certain blood cancers may be at risk for breakthrough COVID-19 infections
Approximately one-quarter of patients with hematologic malignancies did not produce measurable antibodies after two doses of COVID-19 vaccines, according to a study from The Leukemia & Lymphoma Society published in Cancer Cell.
Immunization in cancer survivors: Optimizing response, minimizing risk
The COVID-19 pandemic has underscored the importance of vaccination, both in terms of protecting individuals from infection and eradicating threats to public health.
The case for CAR T cells as earlier treatment requires more evidence
The development of chimeric antigen receptor T cells has provided hope for patients with hematologic malignancies, but their commercial use has been limited to an option of last resort.
FDA lifts hold on clinical trial for allogeneic CAR-T for advanced myeloma
The FDA lifted its clinical hold on a study evaluating UCARTCS1 for the treatment of patients with relapsed or refractory multiple myeloma, according to a press release from the agent’s manufacturer.